SCHEMBL21794075

SCHEMBL21794075

Fc1ccc(F)c(CN2CCCCC2)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.74
SMN1; SMN2 Q16637 2/20 0.74
ALDH1A1 P00352 7/20 0.62
HTT P42858 1/20 0.56
DPP4 P27487 1/20 0.46
DPP8 Q6V1X1 1/20 0.46
DPP9 Q86TI2 1/20 0.46
DPP7 Q9UHL4 1/20 0.46
POLB P06746 2/20 0.45
PKM P14618 1/20 0.45
HRH3 Q9Y5N1 1/20 0.45
TDP1 Q9NUW8 1/20 0.44
CACNB4 O00305 1/20 0.44
CACNA1A O00555 1/20 0.44
CACNA1G O43497 1/20 0.44
CACNG3 O60359 1/20 0.44
CACNA1F O60840 1/20 0.44
CACNA1H O95180 1/20 0.44
CACNB3 P54284 1/20 0.44
CACNA2D1 P54289 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30596583 1.00 KDM4E (0.74) KDM4ESMN1; SMN2ALDH1A1HTTDPP4
SCHEMBL6796135 0.98 KDM4E (0.71) KDM4ESMN1; SMN2ALDH1A1HTTDPP4
SCHEMBL30341003 0.85 KDM4E (1.00) KDM4ESMN1; SMN2ALDH1A1HTTHRH3
SCHEMBL6792953 0.83 KDM4E (0.96) KDM4ESMN1; SMN2ALDH1A1HTTHRH3
SCHEMBL13006258 0.82 MPO (0.58) KDM4ESMN1; SMN2ALDH1A1POLBHRH3
SCHEMBL18712999 0.82 KDM4E (0.51) KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL2922854 0.82 KDM4E (0.51) KDM4ESMN1; SMN2ALDH1A1
SCHEMBL11618145 0.82 KDM4E (0.65) KDM4ESMN1; SMN2ALDH1A1HTTHRH3
SCHEMBL3964348 0.82 KDM4E (0.51) KDM4ESMN1; SMN2ALDH1A1POLBPDE2A
SCHEMBL12139530 0.82 KDM4E (0.65) KDM4ESMN1; SMN2ALDH1A1HTTHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3436446-B1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2023-06-07 EP disclosed
WO-2020047312-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2020-03-05 WO disclosed